{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:01:26Z","timestamp":1778155286722,"version":"3.51.4"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":1954,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1038\/ki.2010.189","type":"journal-article","created":{"date-parts":[[2010,7,30]],"date-time":"2010-07-30T08:10:05Z","timestamp":1280477405000},"page":"S10-S21","source":"Crossref","is-referenced-by-count":95,"special_numbering":"S117","title":["Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals"],"prefix":"10.1016","volume":"78","author":[{"given":"Kamyar","family":"Kalantar-Zadeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuja","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uyen","family":"Duong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rulin C.","family":"Hechter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramanath","family":"Dukkipati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Csaba P.","family":"Kovesdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2010.189_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.ackd.2006.10.005","article-title":"Chronic kidney disease-mineral-bone disorder: a new paradigm","volume":"14","author":"Moe","year":"2007","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1038\/ki.2010.189_bb0015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11255-008-9346-7","article-title":"Bone and mineral disorders in pre-dialysis CKD","volume":"40","author":"Kovesdy","year":"2008","journal-title":"Int Urol Nephrol"},{"key":"10.1038\/ki.2010.189_bb0020","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/ki.2008.35","article-title":"Vitamin D receptor activation and survival in chronic kidney disease","volume":"73","author":"Kovesdy","year":"2008","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.189_bb0025","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/sj.ki.5002800","article-title":"Is parathyroid hormone measurement useful for the diagnosis of renal bone disease?","volume":"73","author":"Drueke","year":"2008","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.189_bb0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/014107680509800408","article-title":"Renal bone disease","volume":"98","author":"Lee","year":"2005","journal-title":"J R Soc Med"},{"key":"10.1038\/ki.2010.189_rf0035","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/j.jrn.2006.07.006","article-title":"Impact of kidney bone disease and its management on survival of patients on dialysis","volume":"17","author":"Lee","year":"2007","journal-title":"J Ren Nutr"},{"issue":"Suppl 1","key":"10.1038\/ki.2010.189_bb0040","first-page":"S1","article-title":"Proceedings of the 18th Annual Meeting of the Japanese Society for Kidney Bone Disease, February 24, 2007, Tokyo, Japan","volume":"11","year":"2007","journal-title":"Ther Apher Dial"},{"key":"10.1038\/ki.2010.189_bb0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.189_bb0050","doi-asserted-by":"crossref","first-page":"F8","DOI":"10.1152\/ajprenal.00336.2004","article-title":"Vitamin D","volume":"289","author":"Dusso","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/ki.2010.189_bb0055","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4158\/EP.14.1.18","article-title":"Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease","volume":"14","author":"Andress","year":"2008","journal-title":"Endocr Pract"},{"key":"10.1038\/ki.2010.189_bb0060","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ncpendmet0394","article-title":"Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease","volume":"3","author":"Brown","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1038\/ki.2010.189_bb0065","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.2215\/CJN.02140309","article-title":"Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease","volume":"4","author":"Kalantar-Zadeh","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.189_bb0070","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2215\/CJN.03850907","article-title":"Battleground: chronic kidney disorders mineral and bone disease \u2013 calcium obsession, vitamin d, and binder confusion","volume":"3","author":"Kovesdy","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.189_bb0075","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1681\/ASN.2004070573","article-title":"Activated injectable vitamin d and hemodialysis survival: a historical cohort study","volume":"16","author":"Teng","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.189_bb0080","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.189_bb0085","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/sj.ki.5001542","article-title":"Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study","volume":"70","author":"Melamed","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.189_bb0090","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ndt\/gfg513","article-title":"Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population","volume":"19","author":"Shoji","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2010.189_bb0095","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/sj.ki.5001868","article-title":"Mortality risk among hemodialysis patients receiving different vitamin D analogs","volume":"70","author":"Tentori","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.189_bb0100","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/ki.2008.343","article-title":"Oral active vitamin D is associated with improved survival in hemodialysis patients","volume":"74","author":"Naves-Diaz","year":"2008","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.189_bb0105","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.2215\/CJN.01760408","article-title":"Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients","volume":"3","author":"Shinaberger","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.189_bb0110","series-title":"J Am Soc Nephrol","article-title":"Impact of activated vitamin D and race on survival among hemodialysis patients","author":"Wolf","year":"2008"},{"key":"10.1038\/ki.2010.189_bb0115","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2007.110","article-title":"Association of activated vitamin D treatment and mortality in chronic kidney disease","volume":"168","author":"Kovesdy","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1038\/ki.2010.189_bb0120","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1681\/ASN.2007111164","article-title":"Association of oral calcitriol with improved survival in nondialyzed CKD","volume":"19","author":"Shoben","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.189_bb0125","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/ndt\/gfn592","article-title":"The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study","volume":"24","author":"Tentori","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2010.189_bb0130","first-page":"295","article-title":"The environment and disease: association or causation?","volume":"58","author":"Hill","year":"1965","journal-title":"Proc R Soc Med"},{"key":"10.1038\/ki.2010.189_bb0135","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1159\/000159247","article-title":"Aortic calcification produced by vitamin D3 plus nicotine","volume":"34","author":"Niederhoffer","year":"1997","journal-title":"J Vasc Res"},{"key":"10.1038\/ki.2010.189_bb0140","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00005344-199508000-00005","article-title":"Progression and regression by verapamil of vitamin D3-induced calcific medial degeneration in coronary arteries of rats","volume":"26","author":"Fleckenstein-Grun","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1038\/ki.2010.189_bb0145","first-page":"51","article-title":"Ultrastructural study of hypervitaminosis D induced arterial calcification in Wistar rats","volume":"16","author":"Kingma","year":"1988","journal-title":"Artery"},{"key":"10.1038\/ki.2010.189_bb0150","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/sj.ki.5002458","article-title":"Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol","volume":"72","author":"Repo","year":"2007","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.189_bb0155","doi-asserted-by":"crossref","first-page":"16810","DOI":"10.1073\/pnas.0611202104","article-title":"Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals","volume":"104","author":"Bodyak","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/ki.2010.189_bb0160","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/sj.ki.5002406","article-title":"Differential effects of vitamin D receptor activators on vascular calcification in uremic rats","volume":"72","author":"Mizobuchi","year":"2007","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.189_bb0165","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1067\/mlc.2002.122819","article-title":"Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport","volume":"139","author":"Brown","year":"2002","journal-title":"J Lab Clin Med"},{"key":"10.1038\/ki.2010.189_bb0170","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/ndt\/gfg296","article-title":"In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3","volume":"18","author":"Hirata","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2010.189_bb0175","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy","volume":"349","author":"Teng","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.189_bb0180","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2215\/CJN.03461006","article-title":"Opposite effects of calcitriol and paricalcitol on the parathyroid hormone-(1\u201384)\/large carboxy-terminal-parathyroid hormone fragments ratio in patients with stage 5 chronic kidney disease","volume":"2","author":"Monier-Faugere","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.189_bb0185","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.2215\/CJN.03140707","article-title":"Whole or fragmentary information on parathyroid hormone?","volume":"2","author":"Drueke","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.189_bb0190","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1210\/en.2002-221026","article-title":"Administration of PTH-(7\u201384) antagonizes the effects of PTH-(1\u201384) on bone in rats with moderate renal failure","volume":"144","author":"Langub","year":"2003","journal-title":"Endocrinology"},{"key":"10.1038\/ki.2010.189_bb0195","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5414\/CNP67131","article-title":"Parathyroid hormone and large related C-terminal fragments increase at different rates with worsening of renal function in chronic kidney disease patients. A possible indicator of bone turnover status?","volume":"67","author":"Donadio","year":"2007","journal-title":"Clin Nephrol"},{"key":"10.1038\/ki.2010.189_bb0200","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1523-1755.2005.00517.x","article-title":"First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl","volume":"68","author":"Martin","year":"2005","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.189_bb0205","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1373\/clinchem.2007.085506","article-title":"An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1 84) is overproduced in parathyroid carcinoma","volume":"53","author":"Rubin","year":"2007","journal-title":"Clin Chem"},{"key":"10.1038\/ki.2010.189_bb0210","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1046\/j.1523-1755.2003.00029.x","article-title":"Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia","volume":"63","author":"Slatopolsky","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.189_bb0215","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0272-6386(03)00905-3","article-title":"K\/DOQI Clinical Practice Guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation I, Kidney Disease-Dialysis Outcome Quality Initiative","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2010.189_bb0220","doi-asserted-by":"crossref","first-page":"c132","DOI":"10.1159\/000098645","article-title":"Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients","volume":"105","author":"Saab","year":"2007","journal-title":"Nephron Clin Pract"},{"key":"10.1038\/ki.2010.189_bb0225","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin D deficiency","volume":"357","author":"Holick","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.189_bb0230","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1681\/ASN.2006060573","article-title":"Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency","volume":"18","author":"London","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.189_bb0235","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/sj.ki.5002451","article-title":"Vitamin D levels and early mortality among incident hemodialysis patients","volume":"72","author":"Wolf","year":"2007","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.189_bb0240","doi-asserted-by":"crossref","first-page":"774","DOI":"10.7326\/0003-4819-88-6-774","article-title":"1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study","volume":"88","author":"Berl","year":"1978","journal-title":"Ann Intern Med"},{"key":"10.1038\/ki.2010.189_bb0245","first-page":"219","article-title":"Long-term administration of vitamin D steroles in incipient and advanced renal failure: effect on bone histology","volume":"10","author":"Malluche","year":"1978","journal-title":"Clin Nephrol"},{"key":"10.1038\/ki.2010.189_bb0250","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/jcem-72-1-157","article-title":"Extrarenal production of calcitriol in normal and uremic humans","volume":"72","author":"Dusso","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/ki.2010.189_bb0255","series-title":"Nephrol Dial Transplant","article-title":"Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism","author":"Block","year":"2008"},{"key":"10.1038\/ki.2010.189_bb0260","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jama.284.8.934","article-title":"Management changes in primary hyperparathyroidism","volume":"284","author":"Irvin","year":"2000","journal-title":"JAMA"},{"key":"10.1038\/ki.2010.189_bb0265","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/ki.2008.64","article-title":"Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease","volume":"73","author":"Kovesdy","year":"2008","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.189_bb0270","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00467-004-1433-0","article-title":"New PTH assays and renal osteodystrophy","volume":"19","author":"Salusky","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"10.1038\/ki.2010.189_bb0275","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1744-9987.2008.00648.x","article-title":"Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients","volume":"12","author":"Guideline Working Group, Japanese Society for Dialysis Therapy","year":"2008","journal-title":"Ther Apher Dial"},{"key":"10.1038\/ki.2010.189_bb0280","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1744-9987.2009.00789.x","article-title":"An overview of regular dialysis treatment in Japan (as of 31 December 2007)","volume":"13","author":"Nakai","year":"2009","journal-title":"Ther Apher Dial"},{"key":"10.1038\/ki.2010.189_bb0285","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1093\/ndt\/gfl395","article-title":"Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders","volume":"21","author":"Galassi","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2010.189_rf0290","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.bone.2007.06.014","article-title":"Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium","volume":"41","author":"Spasovski","year":"2007","journal-title":"Bone"},{"key":"10.1038\/ki.2010.189_bb0295","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.2215\/CJN.01970507","article-title":"Obesity is associated with secondary hyperparathyroidism in men with moderate and severe chronic kidney disease","volume":"2","author":"Kovesdy","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.189_bb0300","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1053\/ajkd.2002.35693","article-title":"Low parathyroid hormone and pentosidine in hemodialysis patients","volume":"40","author":"Panuccio","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2010.189_bb0305","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1525-139X.2005.00073.x","article-title":"Parathyroid hormone assay drift: an unappreciated problem in dialysis patient management","volume":"18","author":"Cantor","year":"2005","journal-title":"Semin Dial"},{"key":"10.1038\/ki.2010.189_bb0310","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/ndt\/gfm849","article-title":"Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study","volume":"23","author":"Melamed","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2010.189_bb0315","first-page":"738","article-title":"Biologic activities of parathyroid hormone (1\u201334) and parathyroid hormone-related peptide (1\u201334) in isolated perfused rat femur","volume":"119","author":"Lopez-Hilker","year":"1992","journal-title":"J Lab Clin Med"},{"key":"10.1038\/ki.2010.189_bb0320","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1542-4758.2009.00380.x","article-title":"Hypoparathyroidism associated with severe mineral bone disease postrenal transplantation, treated successfully with recombinant PTH","volume":"13","author":"Mahajan","year":"2009","journal-title":"Hemodial Int"},{"key":"10.1038\/ki.2010.189_bb0325","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1681\/ASN.2008010014","article-title":"Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients","volume":"19","author":"Regidor","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.189_bb0330","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1744-9987.2007.00540.x","article-title":"Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan","volume":"12","author":"Nakai","year":"2008","journal-title":"Ther Apher Dial"},{"key":"10.1038\/ki.2010.189_bb0335","series-title":"J Ren Nutr","article-title":"Association of relatively low serum parathyroid hormone with malnutrition-inflammation complex and survival in maintenance hemodialysis patients","author":"Dukkipati","year":"2010"},{"key":"10.1038\/ki.2010.189_bb0340","first-page":"496","article-title":"Clinical inquiries. What is the differential diagnosis of an elevated alkaline phosphatase (AP) level in an otherwise asymptomatic patient?","volume":"50","author":"Reust","year":"2001","journal-title":"J Fam Pract"},{"key":"10.1038\/ki.2010.189_bb0345","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1046\/j.1523-1755.2002.00241-1.x","article-title":"Bone alkaline phosphatase isoforms in chronic renal failure","volume":"61","author":"Torres","year":"2002","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.189_bb0350","doi-asserted-by":"crossref","first-page":"c122","DOI":"10.1159\/000086682","article-title":"Bone alkaline phosphatase besides intact parathyroid hormone in hemodialysis patients \u2013 any advantage?","volume":"101","author":"Jorge","year":"2005","journal-title":"Nephron Clin Pract"},{"key":"10.1038\/ki.2010.189_bb0355","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/ki.2008.26","article-title":"Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification","volume":"73","author":"Lomashvili","year":"2008","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.189_bb0360","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ki.2008.104","article-title":"Role for alkaline phosphatase as an inducer of vascular calcification in renal failure?","volume":"73","author":"Schoppet","year":"2008","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.189_bb0365","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1681\/ASN.2004080694","article-title":"Reduced plasma pyrophosphate levels in hemodialysis patients","volume":"16","author":"Lomashvili","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.189_bb0370","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1097\/01.ASN.0000128955.83129.9C","article-title":"Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin","volume":"15","author":"Lomashvili","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.189_bb0375","first-page":"363","article-title":"Inhibition by pyrophosphate and polyphosphate of aortic calcification induced by vitamin D3 in rats","volume":"35","author":"Schibler","year":"1968","journal-title":"Clin Sci"},{"key":"10.1038\/ki.2010.189_bb0380","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1161\/01.RES.0000234909.24367.a9","article-title":"Pyrophosphate, alkaline phosphatase, and vascular calcification","volume":"99","author":"O\u2019Neill","year":"2006","journal-title":"Circ Res"},{"key":"10.1038\/ki.2010.189_bb0385","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.2215\/CJN.06091108","article-title":"Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients","volume":"4","author":"Shantouf","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.189_bb0390","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1210\/jcem.86.3.7327","article-title":"A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial","volume":"86","author":"Lips","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/ki.2010.189_bb0395","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1365-2265.1999.00764.x","article-title":"Vitamin D insufficiency increases bone turnover markers and enhances bone loss at the hip in patients with established vertebral osteoporosis","volume":"51","author":"Sahota","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1038\/ki.2010.189_bb0400","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJM199803193381201","article-title":"Hypovitaminosis D in medical inpatients [see comments]","volume":"338","author":"Thomas","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.189_bb0405","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1542-4758.2009.00430.x","article-title":"Association of serum alkaline phosphatase and bone mineral density in maintenance hemodialysis patients","volume":"14","author":"Park","year":"2010","journal-title":"Hemodial Int"},{"key":"10.1038\/ki.2010.189_bb0410","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1053\/ajkd.2001.28114","article-title":"Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism","volume":"38","author":"Llach","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2010.189_bb0415","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1053\/ajkd.2001.28112","article-title":"Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study","volume":"38","author":"Martin","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2010.189_bb0420","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2215\/CJN.03790808","article-title":"Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients","volume":"4","author":"Belozeroff","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.189_bb0425","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7326\/0003-4819-147-12-200712180-00004","article-title":"Meta-analysis: vitamin D compounds in chronic kidney disease","volume":"147","author":"Palmer","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1038\/ki.2010.189_bb0430","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1053\/j.ajkd.2008.12.040","article-title":"Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients","volume":"53","author":"Kalantar-Zadeh","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2010.189_bb0435","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1681\/ASN.2005010052","article-title":"Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease","volume":"16","author":"Gutierrez","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.189_bb0440","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1053\/j.ajkd.2008.12.002","article-title":"Is it worth correcting hyperparathyroidism if hyperphosphatemia and hypocalcemia worsen? A cinacalcet story","volume":"53","author":"Kalantar-Zadeh","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2010.189_bb0445","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2337\/dc06-2127","article-title":"A1C and survival in maintenance hemodialysis patients","volume":"30","author":"Kalantar-Zadeh","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1038\/ki.2010.189_bb0450","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Gutierrez","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.189_bb0455","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1523-1755.2001.00794.x","article-title":"Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms","volume":"60","author":"Magnusson","year":"2001","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.189_bb0460","doi-asserted-by":"crossref","first-page":"432","DOI":"10.5414\/CNP62432","article-title":"High prevalence of low bone mineral density in pre-dialysis chronic kidney disease patients: bone histomorphometric analysis","volume":"62","author":"Lobao","year":"2004","journal-title":"Clin Nephrol"},{"key":"10.1038\/ki.2010.189_bb0465","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1046\/j.1523-1755.1999.00617.x","article-title":"Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure","volume":"56","author":"Rix","year":"1999","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.189_bb0470","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1210\/jc.2003-030964","article-title":"Aortic calcification and the risk of osteoporosis and fractures","volume":"89","author":"Schulz","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/ki.2010.189_bb0475","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000126925","article-title":"Bone mineral density in end-stage renal disease patients: association with wasting, cardiovascular disease and mortality","volume":"26","author":"Matsubara","year":"2008","journal-title":"Blood Purif"},{"key":"10.1038\/ki.2010.189_bb0480","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/sj.ki.5002585","article-title":"A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease","volume":"73","author":"Fouque","year":"2008","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.189_bb0485","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/sj.ki.5002264","article-title":"Response to \u2018Adynamic Bone Disease and MICS\u2019","volume":"71","author":"Kalantar-Zadeh","year":"2007","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.189_bb0490","first-page":"198","article-title":"Serum albumin levels, an additional factor implicated in hyperparathyroidism outcome in peritoneal dialysis: a prospective study with paired bone biopsies","volume":"22","author":"Sanchez-Gonzalez","year":"2006","journal-title":"Adv Perit Dial"},{"key":"10.1038\/ki.2010.189_bb0495","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1023\/A:1020146023812","article-title":"Interleukin-6 induced suppression of bovine parathyroid hormone secretion","volume":"19","author":"Carlstedt","year":"1999","journal-title":"Biosci Rep"},{"key":"10.1038\/ki.2010.189_bb0500","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1006\/bbrc.1997.7207","article-title":"Inhibition of PTH secretion by interleukin-1 beta in bovine parathyroid glands in vitro is associated with an up-regulation of the calcium-sensing receptor mRNA","volume":"238","author":"Nielsen","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1038\/ki.2010.189_bb0505","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1517\/13543784.17.4.451","article-title":"Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease","volume":"17","author":"Kovesdy","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"issue":"Suppl 3","key":"10.1038\/ki.2010.189_bb0510","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.1177\/089686080102103S44","article-title":"Fragility fractures in dialysis and transplant patients. Is it osteoporosis, and how should it be treated?","volume":"21","author":"Hodsman","year":"2001","journal-title":"Perit Dial Int"},{"key":"10.1038\/ki.2010.189_bb0515","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1046\/j.1523-1755.2003.00837.x","article-title":"Total hip bone mass predicts survival in chronic hemodialysis patients","volume":"63","author":"Taal","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.189_bb0520","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.189_bb0525","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/gfl245","article-title":"Anti-RANKL therapy \u2013 implications for the bone-vascular-axis in CKD? Denosumab in post-menopausal women with low bone mineral density","volume":"21","author":"Westenfeld","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2010.189_bb0530","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1525-139X.2007.00261.x","article-title":"Vascular calcification and disordered mineral metabolism in dialysis patients","volume":"20","author":"Kalpakian","year":"2007","journal-title":"Semin Dial"},{"key":"10.1038\/ki.2010.189_bb0535","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.jrn.2006.01.006","article-title":"Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients","volume":"16","author":"Mehrotra","year":"2006","journal-title":"J Ren Nutr"},{"key":"10.1038\/ki.2010.189_bb0540","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1161\/hy1001.096358","article-title":"Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease","volume":"38","author":"Blacher","year":"2001","journal-title":"Hypertension"},{"key":"10.1038\/ki.2010.189_bb0545","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1159\/000294405","article-title":"Total and individual coronary artery calcium scores as independent predictors of mortality in hemodialysis patients","volume":"31","author":"Shantouf","year":"2010","journal-title":"Am J Nephrol"},{"key":"10.1038\/ki.2010.189_rf0550","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/ndt\/gfg414","article-title":"Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality","volume":"18","author":"London","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2010.189_bb0555","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00041552-200307000-00005","article-title":"Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients","volume":"12","author":"Nolan","year":"2003","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1038\/ki.2010.189_bb0560","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1046\/j.1525-139X.2003.160301.x","article-title":"Calcium phosphate metabolism and cardiovascular disease in patients with chronic kidney disease","volume":"16","author":"Block","year":"2003","journal-title":"Semin Dial"},{"key":"10.1038\/ki.2010.189_bb0565","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.jrn.2007.10.019","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial","volume":"18","author":"Suki","year":"2008","journal-title":"J Ren Nutr"},{"key":"10.1038\/ki.2010.189_bb0570","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.189_bb0575","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1053\/j.ajkd.2008.02.298","article-title":"A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study","volume":"51","author":"Qunibi","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2010.189_bb0580","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1525-139X.2007.00309.x","article-title":"Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake","volume":"20","author":"Uribarri","year":"2007","journal-title":"Semin Dial"},{"key":"10.1038\/ki.2010.189_bb0585","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.189_bb0590","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2215\/CJN.06080809","article-title":"Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease","volume":"5","author":"Kalantar-Zadeh","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.189_bb0595","first-page":"89","article-title":"Organic and inorganic dietary phosphorus and its management in chronic kidney disease","volume":"4","author":"Noori","year":"2010","journal-title":"Iran J Kidney Dis"},{"key":"10.1038\/ki.2010.189_bb0600","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2215\/CJN.08601209","article-title":"Association of dietary phosphorus intake and phosphorus to protein ratio with mortality in hemodialysis patients","volume":"5","author":"Noori","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.189_bb0605","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3945\/ajcn.2008.26665","article-title":"Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?","volume":"88","author":"Shinaberger","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"10.1038\/ki.2010.189_bb0610","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ncpneph0124","article-title":"Hypophosphatemia: an evidence-based approach to its clinical consequences and management","volume":"2","author":"Amanzadeh","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1038\/ki.2010.189_bb0615","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/ajcn\/80.2.299","article-title":"Appetite and inflammation, nutrition, anemia and clinical outcome in hemodialysis patients","volume":"80","author":"Kalantar-Zadeh","year":"2004","journal-title":"Am J Clin Nutr"},{"key":"10.1038\/ki.2010.189_bb0620","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/j.ajkd.2006.03.049","article-title":"Longitudinal associations between dietary protein intake and survival in hemodialysis patients","volume":"48","author":"Shinaberger","year":"2006","journal-title":"Am J Kid Dis"},{"key":"10.1038\/ki.2010.189_bb0625","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2010.189_bb0630","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1159\/000169030","article-title":"Hypocalcemia, morbidity, and mortality in end-stage renal disease","volume":"16","author":"Foley","year":"1996","journal-title":"Am J Nephrol"},{"key":"10.1038\/ki.2010.189_bb0635","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1076-7460.2005.04228.x","article-title":"Classic chronic renal failure: hyperkalemia and hypocalcemia","volume":"14","author":"Spodick","year":"2005","journal-title":"Am J Geriatr Cardiol"},{"key":"10.1038\/ki.2010.189_bb0640","first-page":"583","article-title":"Hypophosphatemia and hungry bone syndrome in a dialysis patient with secondary hyperparathyroidism treated with cinacalcet--proposal for an improved monitoring","volume":"52","author":"Nowack","year":"2006","journal-title":"Clin Lab"},{"key":"10.1038\/ki.2010.189_bb0645","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000101727","article-title":"Long-term outcomes of cinacalcet and paricalcitol titration protocol for treatment of secondary hyperparathyroidism","volume":"27","author":"Lazar","year":"2007","journal-title":"Am J Nephrol"},{"key":"10.1038\/ki.2010.189_bb0650","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1525-139X.2007.00248.x","article-title":"Cinacalcet-induced hungry bone syndrome","volume":"20","author":"Lazar","year":"2007","journal-title":"Semin Dial"},{"key":"10.1038\/ki.2010.189_bb0655","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/ndt\/gfl840","article-title":"Implementation of \u2018K\/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease\u2019 after the introduction of cinacalcet in a population of patients on chronic haemodialysis","volume":"22","author":"Arenas","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2010.189_bb0660","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1076-7460.2005.04221.x","article-title":"Hypocalcemia, hyperkalemia, and junctional or sinoventricular rhythm","volume":"14","author":"Spodick","year":"2005","journal-title":"Am J Geriatr Cardiol"},{"key":"10.1038\/ki.2010.189_bb0665","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2215\/CJN.02101205","article-title":"Association of disorders in mineral metabolism with progression of chronic kidney disease","volume":"1","author":"Schwarz","year":"2006","journal-title":"Clin J Am Soc Neph"},{"key":"10.1038\/ki.2010.189_bb0670","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","article-title":"Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism","volume":"68","author":"Cunningham","year":"2005","journal-title":"Kidney Int"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815544645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815544645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T20:02:41Z","timestamp":1591732961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815544645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":133,"alternative-id":["S0085253815544645"],"URL":"https:\/\/doi.org\/10.1038\/ki.2010.189","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}